Effect of Anti-CD20 Monoclonal Antibody, Rituxan, on Cynomolgus Monkey and Human B Cells in a Whole Blood Matrix

Cytometry Part A

Volumn 52, Issue 2, 2003, Pages 101-109

  Vugmeyster, Yulia ^a   Howell, Kathy ^a   Bakshl, Anahid ^a   Flores, Clarissa ^a   Canova Davis, Eleanor ^a  

^a GENENTECH INC   (United States)

Author keywords

B cells; CD2D; Monoclonal Antibody

Indexed keywords

CD20 ANTIGEN; CD40 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; CONCENTRATION RESPONSE; CYTOMETRY; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MONKEY; NONHUMAN; PRIORITY JOURNAL;

EID: 0042321130     PISSN: 15524922     EISSN: None     Source Type: Journal    
DOI: 10.1002/cyto.a.10030     Document Type: Article

References (25)

1. Yoshino N, Ami Y, Terao K, Tashiro F, Honda M. Upgrading of flow cytometric analysis for absolute counts, cytokines and other antigenic molecules of cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies. Exp Anim 2000;49:97-110.
2. + lymphocytes in cynomolgus monkeys are of resting memory T lineage. Int Immunol 1997;9:591-597.
3. Poatr-Mavoungou V, Onanga R, Yaba P, Delicat A, Dubreuil G, Mavoungou E. Comparative analysis of natural killer cell activity, lymphoproliferation and lymphocyte surface antigen expression in non-human primates housed at the CIRMF Primate Center, Gabon. J Med Primatol 2001;30:26-35.
4. Burkly LC. CD40 pathway blockade as an approach to immunotherapy. Adv Exp Med Biol 2001;489:135-152.
5. Gopal AK, Press OW. Clinical applications of anti-CD20 antibodies. J Lab Clin Med 1999;134:445-450.
6. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83:435-445.
7. Boon L, Laman JD, Ortiz-Buijsse A, den Hartog MT, Hoffenberg S, Liu P, Shiau F, de Boer M. Preclinical assessment of anti-CD40 Mab 5D12 in cynomolgus monkeys. Toxicology 2002;174:53-65.
8. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999;26:74-78.
9. Scott SD. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma. Cancer Pract 1998;6:195-197.
10. Flieger D, Renoth S, Beier I, Sauerbruch T, Schmidt-Wolf I. Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cell Immunol 2000;204:55-63.
11. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002;29:2-9.
12. Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology 2001;40:205-211.
13. Gause A, Berek C. Role of B cells in the pathogenesis of rheumatoid arthritis: potential implications for treatment. Biodrugs 2001;15:73-79.
14. Sopper S, Stahl-Hennig C, Demuth M, Johnston IC, Dorríes R, ter Meulen V. Lymphocyte subsets and expression of differentiation markers in blood and lymphoid organs of rhesus monkeys. Cytometry 1997;29:351-362.
15. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98: 3383-3389.
16. Leveille C, R AL-D, Mourad W. CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines. Eur J Immunol 1999;29:65-74.
17. Leveille C, Chandad F, Al-Daccak R, Mourad W. CD40 associates with the MHC class II molecules on human B cells. Eur J Immunol 1999; 29:3516-3526.
18. Szollosi J, Horejsi V, Bene L, Angelisova P, Damjanovich S. Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J Immunol 1996;157:2939-2946.
19. Bradbury LE, Kansas GS, Levy S, Evans RL, Tedder TF. The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol 1992;149:2841-2850.
20. Polyak MJDJP. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 2002;99:3256-3262.
21. 2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121:1121-1132.
22. Calderhead DM, Kosaka Y, Manning EM, Noelle RJ. CD40-CD154 interactions in B-cell signaling. Curr Topics Microbiol Immunol 2000; 245:73-99.
23. Grewal IS, Flavell RA. CD40 and CD154 in cell-mediated immunity. Annu Rev Immunol 1998;16:111-135.
24. Carroll M. Role of complement receptors CD21/CD35 in B lymphocyte activation and survival. Curr Topics Microbiol Immunol 1999; 246:63-69.
25. Reid RR, Woodcock S, Prodeus AP, Austen J, Kobzik L, Hechtman H, Moore FD Jr, Carroll MC. The role of complement receptors CD21/CD35 in positive selection of B-1 cells. Curr Topics Microbiol Immunol 2000;252:57-65.